Perhaps other types of immunomodulatory approaches that target ligands, such as PD-L2 (CA-170 and PDR001), B7-H3 (MGD009 and MGA271), CTLA-4 (ipilimumab and tremelimumab), ICOS (JTX-2011), LAG-3 (BMS-986016), CD137 (urelumab), OX40 (MEDI16469), CD27 (varlilumab), TIM-3 (TSR-022), A2aR (PBF-509), or CD73 (BMS-986179), may be more effective in patients with glioma. This evidence concerns the gene HAVCR2 and central nervous system cancer.